RIP: a human protein involved in tumor necrosis factor signal transduction
AssigneeAmgen Inc.
InventorsVijay R. Baichwal, Jianing Huang, Hailing Hsu, David V. Goeddel
Life of this patent
Estimating the term…
Abstract
The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
Claims30
A recombinant polynucleotide encoding a RIP-Thr514 polypeptide, said polypeptide comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:2, which consecutive amino acid residues comprise the amino acid residue 514 (Thr) of SEQ ID NO:2, wherein the polypeptide is immunologically distinguishable from RIP-Ser514.
An isolated or recombinant RIP-ACA1540-1542 nucleic acid comprising at least 24 consecutive nucleotides of the nucleotide sequence set forth as SEQ ID NO:1, which consecutive nucleotides comprise nucleotides 1540–1542 (ACA) of SEQ ID NO:1, wherein the nucleic acid hybridizes with RIP-ACA1540-1542 cDNA but not with RIP-TCT1540-1542 cDNA.
Dependencies are inferred from the claim text.